Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2002
04/18/2002US20020045241 T cells specific for kidney carcinoma
04/18/2002US20020045240 Solid phase extraction of the sources containing the components to be separated on anion exchanger materials in loose bulk, on membranes and/or on compact disks,removal of effluent; elution of adsorbed material, fractionation
04/18/2002US20020045235 IKB kinase, subunits thereof, and methods of using same
04/18/2002US20020045218 Nucleotide sequences coding fusion protein for use in the diagnosis and prevention of bacterial infections
04/18/2002US20020045216 Nucleotide sequences coding binding protein; for use in treatment of infections, pain, cancers, diabetes, dietetics, eating disorders, asthma, heart defects, parkinson's, osteoporosis, and nervous system and psychological disorders
04/18/2002US20020045215 Isolation and characterization of a rat epidermal growth factor related protein
04/18/2002US20020045213 IL-17 receptor like molecules and uses thereof
04/18/2002US20020045212 Nucleotide sequences coding preferential polypeptides for use in the treatment of alzheimer's, parkinson's, autoimmune, psoraisis, leukemia, infections, and skin disorders
04/18/2002US20020045211 Plasmid for use in the generation of genetically engineered amino acid sequences
04/18/2002US20020045208 Nucleotide sequences which code polypeptides for use in treatment of autoimmune diseases, allergies and tumors
04/18/2002US20020045206 Contacting the cells with a trophic amount of a ptc therapeutic for promoting survival of substantia nigra neuronal cells
04/18/2002US20020045203 Method for detecting active ingredients of medical value
04/18/2002US20020045202 Enzymatic polypeptide for use in diagnosis, prevention and treatment of inflammatory defects, cancer, diabetes
04/18/2002US20020045197 Methods of determining protein activity levels using gene expression profiles
04/18/2002US20020045191 Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
04/18/2002US20020045186 Inhibition of protein binding to mast cells
04/18/2002US20020045165 Detecting target nucleotide sequences in sample; obtain sample, incubate sample with preferential nucleotides, detect bound sequences, classify sample
04/18/2002US20020045161 Fluorescence resonance energy transfer screening assay for the identification of HIV-1 envelope glycoprotein-medicated cell
04/18/2002US20020044976 Microparticles
04/18/2002US20020044950 Recombinant toxin fragments
04/18/2002US20020044946 12-25 kDa bacterial proteins and their 116-58 kDa polymers useful in anti-tumor vaccines
04/18/2002US20020044944 DNA encoding the polypeptide, with at least one deletion in the amino acid sequence; expression vectors; host cells; higher apoptosis activity
04/18/2002US20020044943 Mucin MUC-1; including organ transplant rejection or graft versus host disease
04/18/2002US20020044941 Nucleic acids, proteins and antibodies
04/18/2002US20020044939 Or Escherichia coli (E. coli) heat labile toxin where in the amino acid sequence, serine-63 and arginine-192 are replaced by another amino acid; vaccines against Vibrio cholera and enterotoxigenic strain of E. coli
04/18/2002US20020044937 Where the protein binds to T-cell cell surface protein, and that complex with nucleic acids, for transporting nucleic acids into human or animal cells which express the T-cell surface protein; antisense therapy, HIV therapy
04/18/2002US20020044936 Administering a monoclonal antibody or fragment thereof which acts as an antagonist of the integrins GPIIb/IIIa ( alpha IIb beta 3) and alpha v beta 3; also treating inflammatory diseases such as rheumatoid arthritis, psoriasis
04/18/2002US20020044935 Peptides of IL-2 and derivatives thereof and their use as therapeutic agents
04/18/2002US20020044933 Inhibition of intimal hyperplasia using antibodies to PDGF receptors
04/18/2002US20020044932 Monocyte chemoattractant activity of galectin-3
04/18/2002US20020044931 Oligopeptides capable of inhibiting interleukin 1 beta converting enzyme (ICE) and preventing cell death; piece of ICE itself inhibits ICE; treating neurodegenerative disorders; liver disorders
04/18/2002US20020044929 Methods for treating sepsis
04/18/2002US20020044928 Immunization of dairy cattle with chimeric GapC protein against streptococcus infection
04/18/2002US20020044927 Use of granulysin as an antimicrobial agent
04/18/2002US20020044925 Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities
04/18/2002US20020044923 Modulating immune responses using antigen presenting human mesenchymal stem cells to induce specific T cell anergy
04/18/2002US20020044922 Recombinant phages
04/18/2002US20020044920 Administration of a therapeutically-effective amount of a TNF antagonist, such as etanercept or infliximab, or a therapeutically-effective amount of a pyrimidine synthesis inhibitor, such as leflunomide
04/18/2002US20020044911 Bacteriophage-encoded enzymes for the treatment and prevention of dental caries and periodontal diseases
04/18/2002US20020044755 Optical fiber with large effective area, low dispersion and low dispersion slope
04/18/2002DE10050070A1 New antiproliferative peptides and nucleic acids useful especially for diagnosis and treatment of tumors, atherosclerosis and psoriasis
04/18/2002DE10049010A1 Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen Transferrin-polycation / DNA complexes for systemic therapy of tumors with cytotoxic proteins
04/18/2002CA2462758A1 Diagnostic indicator of thymic function
04/18/2002CA2462681A1 Disease prevention by reactivation of the thymus
04/18/2002CA2462671A1 Normalization of defective t cell responsiveness through manipulation of thymic regeneration
04/18/2002CA2462081A1 Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
04/18/2002CA2462073A1 Hematopoietic stem cell gene therapy
04/18/2002CA2462046A1 Improvement of graft acceptance through manipulation of thymic regeneration
04/18/2002CA2462027A1 Stimulation of thymus for vaccination development
04/18/2002CA2425835A1 Methods and compositions for nucleic acid delivery
04/18/2002CA2425818A1 Novel human beta2 integrin alpha subunit
04/18/2002CA2425815A1 Treatment of t cell disorders
04/18/2002CA2425779A1 Compositions that inhibit proliferation of cancer cells
04/18/2002CA2425767A1 Lipocalins
04/18/2002CA2425765A1 Novel drugs for liver diseases
04/18/2002CA2425643A1 Cancer-linked genes as targets for chemotherapy
04/18/2002CA2425632A1 Agents for the treatment of viral infections
04/18/2002CA2425610A1 Intracellular delivery of biological effectors by novel transporter peptide sequences
04/18/2002CA2425520A1 N-alkylglycine trimeres capable of blocking the response to chemical substances, heat stimuli or mediators of neuronal receptor inflammation and compositions containing said trimeres
04/18/2002CA2425486A1 Flea peritrophin nucleic acid molecules, proteins and uses thereof
04/18/2002CA2425407A1 Protecting therapeutic compositions from host-mediated inactivation
04/18/2002CA2425359A1 Dioxolane analogs for improved inter-cellular delivery
04/18/2002CA2425356A1 Hedgehog antagonists, methods and uses related thereto
04/18/2002CA2425302A1 Novel polypeptides homologous to thymosin, ephrin a, receptors, and fibromodulin, and polynucleotides encoding same
04/18/2002CA2425298A1 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof
04/18/2002CA2425194A1 Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal
04/18/2002CA2425187A1 Detection of neurodegenerative disorders
04/18/2002CA2424992A1 Paramyxovirus vectors for introducing foreign genes into skeletal muscle
04/18/2002CA2424987A1 Methods of agonizing and antagonizing fabk
04/18/2002CA2424983A1 Nucleic acid molecules and polypeptides for immune modulation
04/18/2002CA2424967A1 Complexes for transferring nucleic acids into cells
04/18/2002CA2424901A1 Genetic control of sex ratio in animal populations
04/18/2002CA2424823A1 Treatment of cancers by aplidine in conjunction with a myoprotector
04/18/2002CA2424433A1 Bvh-a2 and bvh-a3 antigens of group b streptococcus
04/18/2002CA2424055A1 Medication delivery devices
04/18/2002CA2423595A1 Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery
04/18/2002CA2422934A1 Antisense oligonucleotides directed toward mammalian vegf receptor genes and uses thereof
04/18/2002CA2422718A1 Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
04/18/2002CA2394882A1 Dyeing composition promoting natural pigmentation, method for obtaining same and use for colouring the skin and/or keratinous fibres
04/17/2002EP1197556A1 Useful polypeptide
04/17/2002EP1197554A1 Proliferation differentiation factor
04/17/2002EP1197553A1 Antisense nucleic acid against alphaV integrin
04/17/2002EP1197496A1 Novel peptides
04/17/2002EP1197495A2 DNA-binding protein YB-1-containing collagen accumulation inhibitors
04/17/2002EP1197222A2 A stabilized pharmaceutical formulation comprising growth hormone and histidine
04/17/2002EP1197221A1 Preparations stabilized over long time
04/17/2002EP1197220A2 Therapeutic methods and compositions based on delta proteins and nucleic acids
04/17/2002EP1197218A1 Algae protein polysaccharide extraction and use thereof
04/17/2002EP1197032A2 Server-assisted regeneration of a strong secret from a weak secret
04/17/2002EP1196782A1 Catalytic anti-factor viii allo-antibodies
04/17/2002EP1196779A1 Determining antibodies to ny-eso-1 in cancer patients
04/17/2002EP1196773A1 E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death
04/17/2002EP1196772A2 Induction of a th1-like response in vitro
04/17/2002EP1196638A1 USE OF THE i KRIT1 /i GENE IN ANGIOGENESIS
04/17/2002EP1196635A2 Cell death related drug targets in yeast and fungi
04/17/2002EP1196610A2 Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
04/17/2002EP1196609A2 Catalytically active recombinant memapsin and methods of use thereof
04/17/2002EP1196608A2 Novel antifungal agents and fungicides, method for the production thereof and their use
04/17/2002EP1196607A1 Chlamysin b antibacterial protein, gene encoding it and an expression system for it
04/17/2002EP1196600A1 Drosophila recombination-associated protein and methods for use